PrecisION® hnAChR α7/ric3 Recombinant Stable Cell Line

α7 nicotinic acetylcholine (nACh7) receptors are predominantly expressed in the CNS, including the hippocampus, cortex and ventral tegmental area. Nicotinic ACh7 receptors are involved with LTP, memory and attention deficits and so are drug development targets for diseases of cognition including Alzheimer’s and schizophrenia. The nACh7 receptors are rapidly desensitized, have homopentameric architecture and respond to agonists including nicotine, acetylcholine, AR-R17779 and epibatidine. In addition the currents are blocked by the competitive antagonist methyllycaconitine. Drug discovery efforts have also identified positive allosteric modulators such as PNU-120596 which increase the potency of activators such as acetylcholine without causing desensitization. This cell line also expresses the ric3 chaperone protein as when co-expressed with the nACh7 receptor, ric-3 significantly increases surface expression.

Catalog No. Size Price Quantity
CYL3097 2 Vials Inquire

Please contact Customer Service at customerservicedrx@eurofins.com for European (EUR) or United Kingdom (GBP) pricing or log in to see your account-specific pricing.

Related Family Members:

Application
Electrophysiology assay (Conventional and automated patch clamp platforms)
Family
Potassium, Ligand-Gated
Target
nAChR α7/ric3
Accession Number
NM_000746.4
Species
Human
Host Cell Type
HEK 293
Content
2 Vials of mycoplasma-free cells, 1 mL per vial aliquots containing 2M to 4M cells/mL in DMSO
Storage
Vials are to be stored in vapor phase of liquid N2